Gilead Sciences Inc. (GILD)


Analysis of Profitability Ratios
Quarterly Data

Beginner level


Profitability Ratios (Summary)

Gilead Sciences Inc., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Return on Sales
Gross profit margin 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54% 87.06% 86.32% 85.72% 84.52%
Operating profit margin 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03% 67.51% 65.45% 65.14% 62.37%
Net profit margin 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32% 54.62% 52.38% 52.60% 49.44%
Return on Investment
Return on equity (ROE) 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70% 97.12% 92.36% 82.69% 78.45%
Return on assets (ROA) 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93% 33.40% 38.41% 37.07% 34.91%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc.’s ROE deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc.’s ROA improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Gross Profit Margin

Gilead Sciences Inc., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Gross profit on product sales 4,481  4,607  4,243  4,111  4,369  4,344  4,000  4,581  5,370  5,920  5,420  6,141  6,276  6,787  6,488  7,347  7,147  7,128  6,523  6,159  4,981  5,488  4,058 
Product sales 5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681  8,409  8,211  8,126  7,405  7,222  5,968  6,413  4,871 
Profitability Ratio
Gross profit margin1 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54% 87.06% 86.32% 85.72% 84.52%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19% 53.83% 53.39% 52.87% 51.73%
AbbVie Inc. 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31% 81.09% 80.60% 79.12% 77.83%
Allergan PLC 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08% 62.19% 57.25% 53.50% 51.74%
Amgen Inc. 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82% 79.13% 78.27% 78.00% 77.12%
Biogen Inc. 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48% 88.59% 88.36% 88.11% 87.93%
Bristol-Myers Squibb Co. 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39% 76.27% 76.60% 76.34% 75.24%
Eli Lilly & Co. 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76% 75.13% 74.87% 74.96% 74.85%
Johnson & Johnson 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27% 69.20% 69.55% 69.33% 69.40%
Merck & Co. Inc. 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19% 62.70% 62.00% 60.30% 60.30%
Pfizer Inc. 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25% 81.35% 81.14% 80.92% 80.69%
Regeneron Pharmaceuticals Inc. 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43% 91.04% 91.52% 91.99% 92.73%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

1 Q3 2019 Calculation
Gross profit margin = 100 × (Gross profit on product salesQ3 2019 + Gross profit on product salesQ2 2019 + Gross profit on product salesQ1 2019 + Gross profit on product salesQ4 2018) ÷ (Product salesQ3 2019 + Product salesQ2 2019 + Product salesQ1 2019 + Product salesQ4 2018)
= 100 × (4,481 + 4,607 + 4,243 + 4,111) ÷ (5,516 + 5,607 + 5,200 + 5,681) = 79.27%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Operating Profit Margin

Gilead Sciences Inc., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Income (loss) from operations (1,473) 2,430  2,237  1,144  2,623  2,280  2,153  2,291  3,812  4,254  3,767  4,045  4,399  4,538  4,651  5,621  5,585  5,616  5,371  4,330  3,479  4,413  3,043 
Product sales 5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681  8,409  8,211  8,126  7,405  7,222  5,968  6,413  4,871 
Profitability Ratio
Operating profit margin1 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03% 67.51% 65.45% 65.14% 62.37%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05% 14.00% 14.13% 13.95% 12.84%
AbbVie Inc. 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97% 22.86% 19.46% 18.33% 17.09%
Allergan PLC -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00% -17.09% -15.71% -16.60% -9.71%
Amgen Inc. 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44% 37.98% 34.90% 34.51% 32.03%
Biogen Inc. 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44% 46.21% 45.28% 43.63% 40.94%
Bristol-Myers Squibb Co. 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41% 16.40% 16.96% 18.39% 16.32%
Eli Lilly & Co. 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47% 13.53% 11.55% 12.00% 13.56%
Johnson & Johnson 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05% 26.50% 27.31% 28.10% 28.20%
Merck & Co. Inc. 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54% 16.06% 13.62% 12.51% 13.42%
Pfizer Inc. 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20% 25.33% 25.85% 26.09% 26.71%
Regeneron Pharmaceuticals Inc. 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51% 33.30% 31.17% 30.56% 29.74%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

1 Q3 2019 Calculation
Operating profit margin = 100 × (Income (loss) from operationsQ3 2019 + Income (loss) from operationsQ2 2019 + Income (loss) from operationsQ1 2019 + Income (loss) from operationsQ4 2018) ÷ (Product salesQ3 2019 + Product salesQ2 2019 + Product salesQ1 2019 + Product salesQ4 2018)
= 100 × (-1,473 + 2,430 + 2,237 + 1,144) ÷ (5,516 + 5,607 + 5,200 + 5,681) = 19.71%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Net Profit Margin

Gilead Sciences Inc., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566  4,683  4,600  4,492  4,333  3,487  2,731  3,656  2,227 
Product sales 5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681  8,409  8,211  8,126  7,405  7,222  5,968  6,413  4,871 
Profitability Ratio
Net profit margin1 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32% 54.62% 52.38% 52.60% 49.44%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68% 22.17% 22.04% 20.60% 11.28%
AbbVie Inc. 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50% 12.86% 9.93% 8.89% 8.89%
Allergan PLC -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98% 23.16% -15.76% -17.26% -12.48%
Amgen Inc. 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13% 30.94% 28.90% 28.76% 26.69%
Biogen Inc. 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95% 34.06% 33.89% 32.36% 30.25%
Bristol-Myers Squibb Co. 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45% 10.74% 10.93% 13.99% 12.62%
Eli Lilly & Co. 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07% 11.97% 10.50% 11.20% 12.19%
Johnson & Johnson 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99% 20.87% 22.41% 21.63% 21.96%
Merck & Co. Inc. 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25% 27.11% 24.48% 26.98% 28.22%
Pfizer Inc. 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25% 17.45% 18.46% 18.69% 18.42%
Regeneron Pharmaceuticals Inc. 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50% 15.53% 13.56% 11.71% 12.34%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

1 Q3 2019 Calculation
Net profit margin = 100 × (Net income (loss) attributable to GileadQ3 2019 + Net income (loss) attributable to GileadQ2 2019 + Net income (loss) attributable to GileadQ1 2019 + Net income (loss) attributable to GileadQ4 2018) ÷ (Product salesQ3 2019 + Product salesQ2 2019 + Product salesQ1 2019 + Product salesQ4 2018)
= 100 × (-1,165 + 1,880 + 1,975 + 3) ÷ (5,516 + 5,607 + 5,200 + 5,681) = 12.24%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.

Return on Equity (ROE)

Gilead Sciences Inc., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566  4,683  4,600  4,492  4,333  3,487  2,731  3,656  2,227 
Total Gilead stockholders’ equity 20,604  22,616  21,951  21,387  22,861  21,672  20,591  20,442  24,845  22,677  20,441  18,887  16,868  15,536  13,398  18,534  17,414  16,287  17,180  15,426  13,566  16,091  13,387 
Profitability Ratio
ROE1 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70% 97.12% 92.36% 82.69% 78.45%
Benchmarks
ROE, Competitors2
Abbott Laboratories 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85% 21.60% 19.64% 19.21% 10.61%
AbbVie Inc. 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39% 57.93% 37.86% 131.88% 101.84%
Allergan PLC -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11% 4.92% -3.51% -3.14% -5.76%
Amgen Inc. 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71% 23.00% 21.15% 21.53% 20.01%
Biogen Inc. 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84% 34.04% 27.76% 28.09% 27.15%
Bristol-Myers Squibb Co. 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97% 11.77% 11.84% 14.49% 13.49%
Eli Lilly & Co. 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53% 15.49% 14.04% 14.69% 15.55%
Johnson & Johnson 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66% 20.56% 22.64% 23.45% 23.40%
Merck & Co. Inc. 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94% 23.65% 21.21% 23.38% 24.50%
Pfizer Inc. 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75% 12.51% 13.30% 13.64% 12.81%
Regeneron Pharmaceuticals Inc. 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40% 17.93% 13.80% 12.07% 13.69%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

1 Q3 2019 Calculation
ROE = 100 × (Net income (loss) attributable to GileadQ3 2019 + Net income (loss) attributable to GileadQ2 2019 + Net income (loss) attributable to GileadQ1 2019 + Net income (loss) attributable to GileadQ4 2018) ÷ Total Gilead stockholders’ equity
= 100 × (-1,165 + 1,880 + 1,975 + 3) ÷ 20,604 = 13.07%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc.’s ROE deteriorated from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Return on Assets (ROA)

Gilead Sciences Inc., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566  4,683  4,600  4,492  4,333  3,487  2,731  3,656  2,227 
Total assets 59,146  63,210  62,837  63,675  64,305  65,355  65,381  70,283  64,662  60,263  57,701  56,977  56,609  49,980  47,765  51,839  50,637  39,167  38,321  34,664  28,844  31,206  28,078 
Profitability Ratio
ROA1 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93% 33.40% 38.41% 37.07% 34.91%
Benchmarks
ROA, Competitors2
Abbott Laboratories 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72% 10.93% 10.24% 9.75% 5.53%
AbbVie Inc. 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70% 5.14% 3.87% 6.80% 6.44%
Allergan PLC -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88% 2.67% -1.83% -1.61% -3.10%
Amgen Inc. 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69% 8.95% 8.16% 8.28% 7.47%
Biogen Inc. 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19% 17.36% 20.83% 21.53% 20.50%
Bristol-Myers Squibb Co. 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93% 5.59% 5.60% 6.71% 5.94%
Eli Lilly & Co. 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77% 6.50% 5.71% 6.15% 6.43%
Johnson & Johnson 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55% 11.04% 12.20% 12.38% 12.45%
Merck & Co. Inc. 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36% 10.65% 9.60% 10.31% 12.12%
Pfizer Inc. 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16% 4.89% 5.53% 5.72% 5.40%
Regeneron Pharmaceuticals Inc. 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34% 11.41% 10.17% 8.54% 8.99%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-05), 10-Q (filing date: 2015-05-08), 10-K (filing date: 2015-02-25), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-04), 10-Q (filing date: 2014-05-07).

1 Q3 2019 Calculation
ROA = 100 × (Net income (loss) attributable to GileadQ3 2019 + Net income (loss) attributable to GileadQ2 2019 + Net income (loss) attributable to GileadQ1 2019 + Net income (loss) attributable to GileadQ4 2018) ÷ Total assets
= 100 × (-1,165 + 1,880 + 1,975 + 3) ÷ 59,146 = 4.55%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc.’s ROA improved from Q1 2019 to Q2 2019 but then deteriorated significantly from Q2 2019 to Q3 2019.